Study of a new drug for advanced solid tumors
Treatments studied
Part of Cancer clinical trials.
This trial tests a new drug, ART6043, alone or with another drug called olaparib, for people with advanced or metastatic solid tumors. It may help if your cancer has specific DNA repair problems or if you have breast cancer with a BRCA gene mutation.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You have advanced or metastatic cancer that has not responded to standard treatments.
- You have stopped previous cancer treatments for at least 21 days (or 5 half-lives) before starting the study.
- You have recovered from side effects of prior treatments or surgeries.
- You are able to perform daily activities with some help (ECOG performance status 0-2).
- Your organs are functioning well enough to safely take the study drugs.
- If you are of childbearing potential, you must use highly effective contraception.
- You are expected to live at least 12 weeks.
- For Part A2 or Part B: Your tumor has a known DNA repair gene mutation (like BRCA) or you have HER2-negative breast cancer with a BRCA mutation.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a new oral drug, MOMA-313, alone or with another drug (olaparib), in people whose cancer has a specific DNA repair problem (HR-deficient mutation). It aims to see if the drug can shrink tumors or slow their growth.
This trial is testing a new drug, SYN818, combined with olaparib for people with advanced solid tumors that have certain genetic changes (BRCA mutations or related DNA repair problems). It may be an option if you have ovarian or HER2-negative breast cancer and other treatments are no longer working.
This early-phase study tests XL309 (and sometimes a mix of XL309 with another treatment) in people whose advanced solid tumors have specific DNA-repair gene changes, such as BRCA1/2 or other HRR-related changes. It aims to see how well the drug works and what dose is safest for these cancers.
This trial tests a new drug called IMP1734 for people with advanced breast, ovarian, or prostate cancer that has a specific genetic change called an HRR mutation. The drug targets a protein called PARP1 to try to stop cancer cells from repairing themselves.
This trial tests a new drug, SYN608, in people with advanced or metastatic solid tumors, including breast and ovarian cancer, who have run out of standard treatment options. The drug targets tumors with BRCA mutations or other DNA repair problems, which may make them more sensitive to this treatment.
This study tests a new drug called ART0380 for people with advanced solid tumors that have not responded to standard treatments. It may be especially helpful for those with certain DNA repair gene changes (like ATM or BRCA). The drug will be given alone or with chemotherapy (gemcitabine or irinotecan) depending on the part of the trial.
Hear when a new Advanced Solid Tumor trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.